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www.jacctctabstracts2013.com TUESDAY, OCTOBER 29, 2013, 3:30 PM–5:30 PMall-comers setting a TLF rate of 4.7% was observed within the ﬁrst 12 months. The
low TLF rate was also conﬁrmed for pre-deﬁned subgroups: diabetics, acute MI,
small vessel and CTO.
Conclusions: Preliminary data in this "real world" population demonstrates a low TLF
rate comparable to other state of the art DES at 6- and 12-months.
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Background: Guidelines for percutaneous coronary intervention (PCI) specify that
drug-eluting stents (DES) should not be used in patients unable to comply with
prolonged dual antiplatelet therapy. In addition, previous research has suggested that
insurance status is associated with receipt of DES. The impact of socioeconomic
factors upon use of DES has not been previously studied in an underserved population
presenting to a public hospital for PCI.
Methods: Patients undergoing PCI with stenting at Los Angeles County Hospital
were retrospectively analyzed. Multivariable logistic regression was performed, with
receipt of 1 DES as the outcome of interest. Insurance type was categorized as
uninsured, incarcerated, Medicare, Medicaid, and private, based upon primary
insurance at discharge. Race was obtained by patient response on admission and then
deﬁned as Hispanic, African-American, or other (Caucasian, Asian, Native American,
and other) for purposes of comparison.
Results: Among 2763 patients who underwent PCI with stenting, 62.8% received 1
DES. In regards to insurance type, 33.2% were uninsured, 1.7% incarcerated, 22.5%
Medicare, 28.5% Medicaid, and 14.1% private. Self-reported race was 45.4%
Hispanic, 26.8% Caucasian, 11.8% Asian, 6.7% African-American, 0.3% Native
American, and 9.0% other. Patients receiving DES had higher median income by
zipcode, $52835 v. $50432 (p¼0.007). After multivariable adjustment, African-
American and Medicare patients were less likely to receive DES; Medicaid and
uninsured patients were more likely (Table).
Conclusions: Uninsured and government-insured patients were as, or more, likely to
receive DES as patients with private insurance, but African-American patients were
less likely to receive DES. Reasons for this disparity are poorly understood; future
research should focus upon physician perceptions of patient compliance.Variable Odds Ratio 95% CI p value
History of PCI 1.43 1.17-1.74 <0.001
History of CABG 1.54 1.16-2.04 0.003
Current smoking 0.68 0.54-0.85 <0.001
STEMI 0.41 0.31-0.53 <0.001
NSTEMI or unstable angina 1.23 1.01-1.49 0.04
Shock 0.43 0.29-0.63 <0.001
Baseline hematocrit (per 5%) 1.03 1.01-1.05 <0.001
Stent length (per 5 mm) 1.2 1.16-1.23 <0.001
African-American 0.57 0.40-0.82 0.002
Hispanic 0.87 0.72-1.05 0.15
Medicare 0.71 0.52-0.95 0.02
Medicaid 1.49 1.11-2.00 0.008
Incarcerated 0.54 0.27-1.08 0.08
Uninsured 1.51 1.13-2.03 0.006
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Background: Japan-Drug Eluting Stents Evaluation; a Randomized Trial
(J-DESsERT) was the largest randomized trial conducted to directly compare theJACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT Abstrefﬁcacy of sirolimus-eluting stents (SES) over paclitaxel-eluting stents (PES). The aim
of this investigation was to validate the difference in the efﬁcacy and safety of SES vs.
PES over 2 and 3-year follow-up periods.However, this phenomenon has not been
conﬁrmed by well-designed, large scale randomized controlled trials.
Methods: In this largest prospective and multicenter trial, patients were randomized
1:1 to coronary stenting with either SES or PES. Lesion lengths were 46mm with
vessel diameters from 2.5mm to 3.75 mm. Randomization was stratiﬁed based on
the presence or absence of diabetes mellitus (DM). Up to 3 lesions in a maximum of 2
targeted vascular branches could be treated at a time. Target vessel failure (TVF) and
major adverse cardiac cerebrovascular events (MACCE) deﬁned as all death, MI,
TVR, and cerebrovascular accident at 2 years in all populations, and TVF at 3 years
for the DM subset was assessed.
Results: A total of 3,533 patients including 1,724 DM patients were enrolled in this
trial. There was no signiﬁcant difference in patient-characteristics except for the
incidence of stable angina. 65.1% of lesions were B2/C. More than 75% of coronary
artery lesions were assessed via intravascular ultrasound and technical success of stent
deployment was obtained in 98.1% of lesions. PES TVF non-inferiority was not
demonstrated when compared to SES (SES 4.5 % vs PES 6.4%, p¼0.23). SES TVF
was lower than PES in the DM subset. Additionally, SES TVF was lower than PES at
8 months in the DM subset. SES TVF superiority over PES was demonstrated at 12
months in both the DM subset as well as in the entire patient population. (SES 6.0 %
vs PES 9.0 %, p<0.01, SES 7.6% vs PES 10.6% p¼0.03, respectively.) The incidence
of myocardial infarction, stroke, and intervention to remote segments, was almost
identical in both groups.
Conclusions: Final outcomes as demonstrated by 3 year follow-up will be presented
at TCT 2013. This trial will provide deep insight for the long-term efﬁcacy of these
two different types of DES.
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Background: Contemporary second-generation drug-eluting stents (DES) are often
used in complex patients, but there is limited knowledge about potential difference in
outcome between the zotarolimus-eluting Resolute and everolimus-eluting Xience V
stents in these patients.
Methods: We therefore analyzed the 2-year clinical outcome data of 1033 complex
TWENTE trial patients treated with second-generation everolimus-eluting Xience V
or zotarolimus-eluting Resolute stents. The primary endpoint of the TWENTE trial,
target vessel failure, was deﬁned as cardiac death, target vessel-related myocardial
infarction (MI), or target vessel revascularization (TVR).
Results: Among the 1033 complex patients, 529 (51.2%) were treated with Resolute
stents and 504 (48.8%) with Xience V. Patient and procedure-related characteristics
were similar between DES groups. After 2-year follow-up, clinical outcome was also
similar between DES groups. In patients treated with Resolute and Xience V, TVF
occurred in 12.1% and 12.3% of patients, respectively. In addition, DES groups did
not differ in cardiac death, MI, or TVR, the individual components of TVF.Conclusions: Complex patients treated with zotarolimus-eluting Resolute and ever-
olimus-eluting Xience V stents showed similar safety and efﬁcacy during 2-year
follow-up.acts/POSTER/Bare Metal and Drug-Eluting Stent Studies B55
